Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study

The Lancet

Volumn 389, Issue 10065, 2017, Pages 157-166

  Reddel, Helen K ^a   Busse, William W ^b   Pedersen, Søren ^c   Tan, Wan C ^d   Chen, Yu Zhi ^e   Jorup, Carin ^f   Lythgoe, Dan ^g   O'Byrne, Paul M ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CAPITAL INSTITUTE OF PEDIATRICS   (China)

^f ASTRAZENECA R AND D   (Sweden)

^g PHASTAR   (United Kingdom)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BRONCHODILATING AGENT; CORTICOSTEROID;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMERGENCY TREATMENT; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SLEEP; SYMPTOM; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PRESCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC;

EID: 85007500726     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31399-X     Document Type: Article

References (32)

1. 1 Laitinen, LA, Laitinen, A, Haahtela, T, Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 147 (1993), 697–704.
2. 2 Vignola, AM, Bousquet, J, Chanez, P, et al. Assessment of airway inflammation in asthma. Am J Respir Crit Care Med 157 (1998), S184–S187.
3. 3 Adams, N, Bestall, J, Jones, PW, Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev, 4, 2001 CD003274.
4. 4 Suissa, S, Ernst, P, Benayoun, S, Baltzan, M, Cai, B, Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343 (2000), 332–336.
5. 5 Suissa, S, Ernst, P, Kezouh, A, Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 57 (2002), 880–884.
6. 6 Reddel, HK, Taylor, DR, Bateman, ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180 (2009), 59–99.
7. 7 Masoli, M, Holt, S, Weatherall, M, Beasley, R, Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 23 (2004), 552–558.
8. 8 Woolcock, A, Rubinfeld, AR, Seale, JP, et al. Thoracic Society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust 151 (1989), 650–653.
9. 9 National Heart Lung, Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur Respir J 5 (1992), 601–641.
10. 10 British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma, 2014, Edinburgh, Scottish Intercollegiate Guidelines Network.
11. 11 National Asthma and Education Campaign Expert Panel Report 3. Asthma care quick reference, 2012, National Heart, Lung, and Blood Institute, Bethesda, MD.
12. 12 GINA. Global strategy for asthma management and prevention. Revised 2014, 2014, Global Initiative for Asthma, Vancouver, USA.
13. 13 Pauwels, RA, Pedersen, S, Busse, WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361 (2003), 1071–1076.
14. 14 O'Byrne, PM, Pedersen, S, Busse, WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 129 (2006), 1478–1485.
15. 15 O'Byrne, PM, Pedersen, S, Lamm, CJ, Tan, WC, Busse, WW, Start Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179 (2009), 19–24.
16. 16 Boulet, LP, Turcotte, H, Prince, P, et al. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Respir Med 103 (2009), 1554–1563.
17. 17 Reddel, HK, Belousova, EG, Marks, GB, Jenkins, CR, Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Prim Care Respir J 17 (2008), 39–45.
18. 18 Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 343 (2000), 1054–1063.
19. 19 O'Byrne, PM, Barnes, PJ, Rodriguez-Roisin, R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001), 1392–1397.
20. 20 Postma, DS, O'Byrne, PM, Pedersen, S, Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control. Chest 139 (2011), 311–318.
21. 21 Dusser, D, Montani, D, Chanez, P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 62 (2007), 591–604.
22. 22 Campbell, DA, McLennan, G, Coates, JR, et al. A comparison of asthma deaths and near-fatal asthma attacks in South Australia. Eur Respir J 7 (1994), 490–497.
23. 23 Robertson, CF, Rubinfeld, AR, Bowes, G, Deaths from asthma in Victoria: a 12-month survey. Med J Aust 152 (1990), 511–517.
24. 24 Sullivan, SD, Buxton, M, Andersson, LF, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 112 (2003), 1229–1236.
25. 25 Buxton, MJ, Sullivan, SD, Andersson, LF, et al. Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. Eur Respir J 24 (2004), 568–574.
26. 26 Fuhlbrigge, AL, Kelly, HW, Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med 2 (2014), 487–496.
27. 27 Peters, SP, Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc 98 (2006), 851–861.
28. 28 Beasley, R, Weatherall, M, Shirtcliffe, P, Hancox, R, Reddel, HK, Combination corticosteroid/beta-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?. J Allergy Clin Immunol 133 (2014), 39–41.
29. 29 Calhoun, WJ, Ameredes, BT, King, TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 308 (2012), 987–997.
30. 30 Martinez, FD, Chinchilli, VM, Morgan, WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 377 (2011), 650–657.
31. 31 Papi, A, Canonica, GW, Maestrelli, P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356 (2007), 2040–2052.
32. 32 Haahtela, T, Tamminen, K, Malmberg, LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J 28 (2006), 748–755.